links for 2009-05-16
-
Bayer's cancer drug Nexavar showed promise as a lung-cancer treatment in a Phase II study, the ASCO association of U.S. oncologists said on its Website on Friday. The authors of the Phase II study, which will be presented in detail at ASCO's annual meeting at the end of this month, concluded that the combination of Nexavar and Roche's approved lung cancer drug Tarceva "is safe and has clinically significant anti-tumour activity."